Mckesson Stock News

Johnson & Johnson (JNJ) and three leading drug distributors in the U.S., Cardinal Health (CAH), McKesson Corporation (MCK), and AmerisourceBergen (ABC), continue to draw the ire…

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a

NEW YORK (AP) — Releasing years of anguish and anger, victims of opioid abuse and those who have lost loved ones to an addiction crisis stretching back more than two decades unloaded their emotions on members of the family they blame for fueling the deadly epidemic. Thursday’s unusual hearing, conducted virtually in U.S. Bankruptcy Court, gave them what they have wanted for years: the chance to confront members of the Sackler family who own OxyContin maker Purdue Pharma and tell them about the lasting pain that addiction and overdoses have had in their lives. “When you created OxyContin, you created so much loss for so many people. … I’m outraged that you haven’t owned up to the crisis that you’ve created," said Kay Scarpone, addressing the three Sackler family members in attendance. She lost her son Joseph Scarpone, a former marine, to addiction a month before his 26th birthday. Appearing only via audio was Richard Sackler, the former Purdue president and board chair who has said the company and family bear no responsibility for the opioid crisis, and also a son of Raymond Sackler, one of the three brothers who in the 1950s bought the company that became Purdue Pharma.

McKesson Corporation found using ticker (MCK) now have 13 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 300 and 230 calculating the average target price we see 268.08. Given that the stocks previous close was at 272.75 this is indicating there is a potential downside of -1.7%. There is a 50 day moving average of 261.13 and the 200 day moving average is 219.28. The company has a market capitalisation of $42,221m. You can visit the company''s website by visiting: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets=MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $41,498m based on the market concensus. McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).

Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Drug distributors McKesson, AmerisourceBergen and Cardinal Health are part of the settlement.

The three largest pharmaceutical distributors have approved the $19.5 billion settlement with states and municipalities over expenses of the opioid crisis.

Johnson & Johnson (NYSE: JNJ ) shares are trading higher Friday after the company agreed to finalize a proposed $26 billion settlement resolving more than 3,000 lawsuits, mainly by state and local governments, seeking to hold it and three other companies responsible for the opioid abuse crisis. The other companies are distributors McKesson Corp (NYSE: MCK ), AmerisourceBergen Corp (NYSE: ABC ) and Cardinal Health Inc (NYSE: CAH ). Johnson & Johnson was up 4.97% at $166 Friday afternoon at publication. See Also: Drug Distributors, JNJ Agree To Settle $26B Opioid Lawsuits Johnson & Johnson Daily Chart Analysis The stock recently bounced off support in a sideways channel and has been pushing higher, now nearing the resistance level of the channel. Support was found near … Full story available on Benzinga.com

Drugmaker Johnson & Johnson and three major distributors finalized nationwide settlements over their role in the opioid addiction crisis Friday, an announcement that clears the way for $26 billion to flow to nearly every state and local government in the U.S. Taken together, the settlements are the largest to date among the many opioid-related cases that have been playing out across the country. They''re expected to provide a significant boost to efforts aimed at reversing the crisis in places that have been devastated by it, including many parts of rural America. Johnson & Johnson, AmerisourceBergen, Cardinal Health and McKesson announced the settlement plan last year, but the deal was contingent on getting participation from a critical mass of state and local governments. Friday was the deadline for the companies to announce whether they felt enough governments had committed to participate in the settlement and relinquish the right to sue. The four companies notified lawyers for the governments in the case that their thresholds were met, meaning money could start flowing to communities by April. "We''re never going to have enough money to immediately cure this problem," said Joe Rice, one of the lead lawyers who represented local governments in the litigation that led to the settlement. "What we''re trying to do is give a lot of small communities a chance to try to change some of their problems." While none of the settlement money will go directly to victims of opioid addiction or their survivors, the vast majority of it is required to be used to deal with the epidemic.

MADISON, Wis. – Attorney General Kaul announced today the final approval of the $26 billion opioid agreement with the nation’s three major pharmaceutical distributors – Cardinal, McKesson, and AmerisourceBergen – and Johnson & Johnson. Following successful state sign-on and subdivision sign-on periods, the defendants will start releasing funds to a national administrator on April 2, […]

Distributors McKesson Corporation (NYSE: MCK ), AmerisourceBergen Corp (NYSE: ABC ), Cardinal Health Inc (NYSE: CAH ), and Johnson & Johnson (NYSE: JNJ ) have agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments regarding the opioid epidemic. The deal aims to resolve more than 3,000 lawsuits, mainly by state and local governments seeking to hold the companies responsible for … Full story available on Benzinga.com

AmerisourceBergen, Cardinal Health and McKesson said they would proceed with a settlement of the majority of the opioid lawsuits filed by state and local governments in the U.S.

AmerisourceBergen, Cardinal Health and McKesson said they agreed to proceed with a settlement of the majority of the opioid lawsuits filed by state and local governments in the U.S.